Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | PHASE3 | RECRUITING | 720 | — | — | Sep 8, 2025 | Dec 1, 2030 | Jun 2, 2026 | 118 | United States, Australia +13 |
| Arm | Type | Description |
|---|---|---|
| Arm A (Experimental Arm) | EXPERIMENTAL | Casdatifan and cabozantinib taken orally |
| Arm B (Comparator Arm) | PLACEBO_COMPARATOR | Placebo and cabozantinib taken orally |
| Name | Type | Description |
|---|---|---|
| Casdatifan | DRUG | Administered as specified in the treatment arm |
| Cabozantinib | DRUG | Administered as specified in the treatment arm |
| Placebo | DRUG | Administered as specified in the treatment arm |
Inclusion Criteria: * Unresectable and measurable locally advanced or metastatic renal cell carcinoma with a primary clear cell component. * A Karnofsky Performance Status (KPS) score ≥ 80% * At least 1 target lesion measurable by computed tomography/magnetic resonance imaging per RECIST 1.1, not w...